Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benefit-Risk Assessment Framework Pushes Into Post-Approval Arena

Executive Summary

An industry/regulator working group will flesh out the processes involved in the eight-step framework and identify data that can be used at each step, in both the pre-market and post-market stage.

You may also be interested in...



FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014

Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.

EU Pharmacovigilance Fees Could Cripple Drug Firms, Says Pharma Industry

Fees set to be introduced to cover the cost of the European Medicines Agency’s part in improving drug safety could impose a huge burden on the EU pharmaceutical industry and lead to the closure of smaller firms, the industry says.

International Group Finds Harmony In Benefit-Risk Assessment Framework

Sponsors and regulators continue to develop methodologies with a range of complexity for presenting, communicating and discussing a drug’s risks and benefits.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel